← Oncology Approval Tracker

FDA DECISION ·

Keytruda

pembrolizumab · Merck

Traditional approvalTraditional conversionHepatocellular carcinoma
Open LinkedIn brief ↓

1 min read · estimated

Sources

APPROVED USE

What FDA approved

Patients with hepatocellular carcinoma caused by hepatitis B who have received prior systemic therapy other than a PD-1 or PD-L1 inhibitor-containing regimen.

LAMPGEN ANALYSIS

Why it matters

Traditional approval followed confirmatory review and revised the previously accelerated indication to a hepatitis B-associated population.

What research teams should watch

Record tumor etiology and prior checkpoint exposure and coordinate hepatitis B treatment and liver laboratory monitoring.

PRIMARY RECORDS

Sources